Akili raises an additional $11.9M; brings Amgen, Merck, Pfizer and Shire to the digital medicine table

—– Akili Adds Amgen Ventures and M Ventures* to Series B Financing, Increasing Round to $42.4 Million (press release): “Akili Interactive Labs, Inc. (“Akili”), a digital medicine company developing novel, non-pharmacological therapeutics and diagnostics for cognitive disorders, today announced an $11.9 million expansion of its recent Series B financing. Merck Ventures BV, Amsterdam, The Netherlands, a subsidiary of Merck KGaA, Darmstadt, Germany (known as M Ventures in the United States and Canada), and Amgen Ventures, the venture arm of Amgen, joined existing investors to bring the total Series B proceeds to $42.4 million. Akili will use the funds to support and expand clinical development of its clinical-stage products into new areas, with an expanded focus on neurodegeneration, and to build out its commercial infrastructure as Akili nears the market with its late-stage products. With the M Ventures and Amgen Ventures investments, Akili now has four relationships with major biopharma companies or their investment affiliates, including its existing partnership with Pfizer, Inc. and an investment from Shire Pharmaceuticals. …said Eddie Martucci, Ph.D., Co-founder and Chief Executive Officer of Akili. “There exists a tremendous opportunity to deliver medicine that is efficacious and addresses the needs for safe, non-pharmacological treatments in many neurological and mental health patient populations. M Ventures’ and Amgen Ventures’ support, combined with tha...
Source: SharpBrains - Category: Neuroscience Authors: Tags: Attention and ADD/ADHD Cognitive Neuroscience Health & Wellness Technology Akili Akili Interactive Labs Amgen Ventures biopharma cognitive--disorders diagnostics digital medicine Merck Ventures neurodegeneration neurological no Source Type: blogs